TB-500 Protocol

Evidence Level: Investigational / Theoretical

Primarily preclinical or very limited human data — mechanism-based reasoning more than a demonstrated clinical effect. Treat as investigational.

Human evidence: No controlled human trials specific to the isolated TB-500 fragment.

Animal evidence: Rodent wound-healing and cardiac-repair studies inform the mechanism.

Introduction & Mechanism of Action

Research associated with thymosin-beta-4-related cell migration and repair signaling.

Synthetic fragment of thymosin beta-4, an actin-binding protein studied for promoting cell migration, angiogenesis and reduced inflammation in animal injury models.

Receptors/targets: No classical receptor — proposed mechanism is intracellular actin-binding and downstream signaling

Areas of Research Interest

• Cell migration research
• Repair signaling
• Angiogenesis models

Benefits Reported in Research

• Cell-migration research
• Recovery and mobility studies
• Angiogenesis research

Reported Research Dosing Range

The figures below are cited from published research literature and protocol references — they describe what has been studied, not a personal prescription or instruction.

Reported range: 500–1000 mcg

Reported frequency: 1× daily, subcutaneous

Reported cycle duration: 8–12 weeks

Escalation & maintenance: A dedicated weekly escalation and maintenance schedule specific to this peptide has not yet been published here — follow the dose range and frequency above, titrating conservatively from the low end, and consult a physician before adjusting.

Research Reference Data

Published research on TB-500 reports administration at 500–1000 mcg via subcutaneous route. The table below cites that published research — it is not an individualized instruction.

Reconstitution Reference

Published research protocols reconstitute a 5 mg vial with 2 mL bacteriostatic water, yielding a concentration of 2.50 mg/mL. This is cited reference information, not a personalized preparation instruction — use the general research calculator below for your own reference computation.

Research Protocol Timeline

A reference summary of how this compound is described across published research — formulation, reported administration, and reported cycle length.

Dilution Guide

Reconstitute with 2 mL bacteriostatic water

Bacteriostatic Water (BAC Water) is the only recommended diluent. Do not dilute with sterile water, normal saline, lidocaine, or any other solution unless explicitly specified by the manufacturer.

Handling Guide

General laboratory handling practice cited for reference — not a personalized instruction. Any human use should follow the guidance of a licensed physician.

Wash hands and clean the injection site with an alcohol swab. Pinch a fold of skin and insert the needle at a 45–90° angle for standard subcutaneous injection (abdomen, thigh, or upper arm). Inject slowly, withdraw, and apply gentle pressure. Rotate injection sites to reduce irritation, and dispose of needles in an approved sharps container.

Storage

Store lyophilized (powder) vials in a freezer at -20°C, protected from light. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within the timeframe recommended in your supplier documentation — typically 2–4 weeks.

Monitoring

Monitor for injection-site reactions and the side effects listed above. Stop use and consult a physician if severe or persistent reactions occur. This is a general monitoring guideline, not a personalized medical monitoring plan.

Side Effects

• Injection-site irritation
• Fatigue (anecdotal)

Contraindications

• Pregnancy
• Active malignancy (theoretical concern given angiogenic mechanism)

Drug interactions

• Not characterized — no controlled human drug-interaction studies exist

Safety

• No meaningful human safety database
• FDA reports no identified human exposure data for the isolated fragment

TB-500 should not be conflated with all thymosin beta-4 research. FDA reports no identified human exposure data for the fragment and insufficient safety information.

Expected Results & Comparison

TB-500 should not be conflated with the broader thymosin beta-4 research literature, which includes some human trial work on the intact protein — the isolated fragment sold as "TB-500" has its own, sparser evidence base.

References

Continue